Clinical Trials in MDS and Acute Myeloid Leukaemia (AML)

 

Trial Name

 

Trial Summary

 

Hyperlink

 

Li-1

 

This trial is looking at new drugs in combination with cytarabine (Ara C) for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS).

 

 

AML18

 

This trial is looking at treatment for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). It is designed mainly for people over 60 years of age who are fit enough to have intensive chemotherapy. But some younger people may be able to take part.

 

 

AML19

 

This trial is looking at different treatments for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). It is for people who are fit enough to have intensive treatment.

 

 

MIRROS

 

This trial is for people whose acute myeloid leukaemia (AML) has come back or continued to grow following their first or second treatment.

 

 

CCS1477

 

An early phase trial testing the oral medication CCS1477. This trial is for patients who have relapsed (has come back after treatment) or refractory (not responded to treatment) acute myeloid leukaemia (AML).

 

 

FIBROGEN Roxadustat

         A trial for patients with 'very low', 'low', 'intermediate' risk MDS - who receive regular blood transfusions (1-4 within 8 weeks).